AR095555A1 - Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf) - Google Patents

Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)

Info

Publication number
AR095555A1
AR095555A1 ARP140101177A ARP140101177A AR095555A1 AR 095555 A1 AR095555 A1 AR 095555A1 AR P140101177 A ARP140101177 A AR P140101177A AR P140101177 A ARP140101177 A AR P140101177A AR 095555 A1 AR095555 A1 AR 095555A1
Authority
AR
Argentina
Prior art keywords
hgf
antibodies
hepatocite
growth factor
antibodies directed
Prior art date
Application number
ARP140101177A
Other languages
English (en)
Inventor
L Feldhaus Andrew
Anderson Katie
H Dutzar Benjamin
A Latham John
F Garca-Martnez Len
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of AR095555A1 publication Critical patent/AR095555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpos y fragmentos de anticuerpos (que en especial pueden ser quiméricos o humanizados) dirigidos específicamente al HGF y su uso en la terapia y en el diagnóstico. Estos anticuerpos pueden inhibir o bloquear las actividades asociadas al HGF, incluyendo el efecto del HGF sobre la proliferación de las células, sobre su capacidad de invasión, sobre la angiogenesis, sobre las metástasis y sobre la fibrosis. En particular, estos anticuerpos pueden usarse como monoterapias o en combinación con otras terapias. en el contexto del tratamiento del cáncer, de otras enfermedades relacionadas con la proliferación o de otras afecciones donde puede resultar deseable inhibir el HGF y/o la interacción entre el HGF y al miembro de la clase IV de la familia de receptores de proteína tirosina quinasa (HGF o C-met).
ARP140101177A 2013-03-14 2014-03-17 Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf) AR095555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361781643P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095555A1 true AR095555A1 (es) 2015-10-28

Family

ID=51527870

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140101177A AR095555A1 (es) 2013-03-14 2014-03-17 Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)
ARP140101178A AR095556A1 (es) 2013-03-14 2014-03-17 Anticuerpos contra hgf y composiciones que contienen a los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140101178A AR095556A1 (es) 2013-03-14 2014-03-17 Anticuerpos contra hgf y composiciones que contienen a los mismos

Country Status (2)

Country Link
US (1) US9732150B2 (es)
AR (2) AR095555A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA2997801A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3645049A4 (en) 2017-06-25 2021-06-30 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND ASSOCIATED PREPARATION AND USE PROCESSES
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP4031574A1 (en) 2019-09-16 2022-07-27 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
BR112022008683A2 (pt) 2019-11-05 2022-07-19 Abbvie Inc Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
BRPI0712222B1 (pt) * 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
KR20190112175A (ko) * 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도

Also Published As

Publication number Publication date
US20140271464A1 (en) 2014-09-18
US9732150B2 (en) 2017-08-15
AR095556A1 (es) 2015-10-28

Similar Documents

Publication Publication Date Title
AR095555A1 (es) Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
MX2018003898A (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas.
EA201892386A1 (ru) Химерные нейротоксины
EA201890278A1 (ru) Антитела к pd-l1
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
AR089978A1 (es) Translocaciones de la r-espondina y sus metodos de uso, metodo de tratamiento, antagonistas
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
UY35258A (es) ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PE20151871A1 (es) Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
CL2015002835A1 (es) Nuevos derivados de piridina
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares

Legal Events

Date Code Title Description
FB Suspension of granting procedure